- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00611715
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with erlotinib may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying how well giving letrozole together with erlotinib works in treating postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally recurrent or metastatic breast cancer.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
Primary
- To determine the rate of clinical benefit (complete response [CR], partial response [PR], and stable disease [SD] in patients with hormone-dependent locally recurrent or metastatic breast cancer treated with letrozole in combination with erlotinib hydrochloride.
Secondary
- To determine the time to progression (TTP) in patients treated with this regimen.
- To evaluate the anti-tumor activity, as determined by CR and PR rates, of this regimen in these patients.
- To evaluate the safety of this regimen in these patients.
- To determine if tumors that are positive for epidermal growth factor receptor (EGFR) or Ser118 ER, or that overexpress human epidermal receptor (HER2) exhibit a longer TTP from the combination compared to tumors that do not express or overexpress these molecules.
OUTLINE: This is a multicenter study. Patients are stratified according to prior hormone therapy (hormone-therapy naive/first-line therapy vs prior hormonal therapy with either tamoxifen or an aromatase inhibitor in the adjuvant or metastatic setting/second-line therapy)
Patients receive oral letrozole and oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Georgia
-
Macon, Georgia, Stati Uniti, 31201
- Central Georgia Hematology/Oncology Associates, P.C.
-
-
Kentucky
-
Hopkinsville, Kentucky, Stati Uniti, 42240
- Jennie Stuart Medical Center
-
Paducah, Kentucky, Stati Uniti, 42002
- Purchase Cancer Group
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Memorial Health Care System
-
Germantown, Tennessee, Stati Uniti, 38138
- The Jones Clinic - Germantown
-
Jackson, Tennessee, Stati Uniti, 38301
- Jackson-Madison County Hospital
-
Knoxville, Tennessee, Stati Uniti, 37909
- Tennessee Cancer Specialists
-
Nashville, Tennessee, Stati Uniti, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, Stati Uniti, 37067
- Vanderbilt-Ingram Cancer Center - Cool Springs
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- Patients must have estrogen (ER) and/or progesterone receptor (PgR)-positive, histologically confirmed adenocarcinoma of the breast with measurable (but not operable) locally recurrent disease, or measurable and/or evaluable metastatic disease (see protocol section 10.3), including isolated bone metastases.
- Patients with available paraffin tissue blocks from either the primary or the metastatic site must submit tissue blocks for retrospective EGFR and HER2 analysis. If tissue blocks cannot be submitted, 20 unstained slides from each paraffin block must be submitted.
All patients must be post-menopausal females as defined by one of the following:
- Prior bilateral oophorectomy
- Prior bilateral ovarian irradiation
- No menstrual period for 12 months or longer
- If age 55 years or less and < 12 months from last menstrual period, patient must have a serum estradiol < or equal to 30 and an FSH level > 40.
- Patients must not have had more than 1 prior chemotherapy regimen for metastatic disease and have fully recovered from any grade 2-4 toxicities related to chemotherapy. No concurrent chemotherapy is allowed while on protocol therapy.
- Patients may have had 1 prior hormonal therapy for metastatic disease. This includes: tamoxifen, fulvestrant, anastrozole, exemestane, aminoglutethimide, megace, and letrozole. Patients may have received tamoxifen or aromatase inhibitors in the adjuvant setting.
- Patients must not have had prior therapy with EGF receptor inhibitors.
- Previous but not concomitant therapy with trastuzumab (Herceptin) is allowed. Patients must not have received Herceptin within 4 weeks of initiation of protocol therapy.
- Patients must have an ECOG performance status of 0, 1, or 2.
Patients must have adequate hematologic, hepatic, and renal function as defined by the following within 2 weeks of initiation of therapy:
- Absolute neutrophils > or equal to 1,500/mm3 and platelets > or equal to 100,000/mm3.
- Bilirubin < than or equal to 1.5 upper limit of normal.
- SGOT and SGPT < or equal to 2.5 upper limit of normal.
- Creatinine < or equal to 1.5 upper limit of normal.
- INR, PTT and PT in the normal range.
- Must be 18 years of age or older.
- Patients must not have a history of central nervous system metastases or unevaluated CNS symptoms suggestive of possible brain metastases.
- Patients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry and sites of evaluable disease outside the radiation port(s) are available for follow-up. Patients who have received prior radiotherapy must have recovered from toxicity induced by this treatment.
- Patients < 55 years of age must not have received Luteinizing hormone releasing hormone (LHRH) antagonists within 3 months prior to protocol therapy.
- Patients must not suffer from medical or psychiatric conditions that would interfere with ability to provide informed consent, communicate side effects, or comply with protocol requirements including maintenance of a compliance/pill diary.
- Patients must be disease-free of prior invasive cancers for > 5 years with the exception of basal or squamous cancer of the skin or cervical carcinoma in situ.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: First line/hormone-therapy naive
|
OSI-774 150 mg/day
Altri nomi:
Letrozole 2.5 mg/day
Altri nomi:
To determine HER2 gene amplification or excess copies of the HER2 gene
Altri nomi:
to measure the epidermal growth factor receptors (EGFR)
Altri nomi:
To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Altri nomi:
|
Sperimentale: Second-line/prev hormone-therapy tx
|
OSI-774 150 mg/day
Altri nomi:
Letrozole 2.5 mg/day
Altri nomi:
To determine HER2 gene amplification or excess copies of the HER2 gene
Altri nomi:
to measure the epidermal growth factor receptors (EGFR)
Altri nomi:
To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Patients With Pathological Complete Response.
Lasso di tempo: at 24 weeks
|
Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions
|
at 24 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Median Time to Progression of Target Lesions
Lasso di tempo: Every 12 weeks from on-study to disease progression
|
Time frame from study entry till discontinuation of treatment due to disease progression.
Progression of target lesions is measured by RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions.
|
Every 12 weeks from on-study to disease progression
|
Number of Patients With Anti-tumor Activity: Complete Response (CR) and Partial Response (PR)
Lasso di tempo: at 24 weeks
|
Per RECIST criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions and partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions.
|
at 24 weeks
|
Number of Patients With Worst-grade Toxicities Per Grade
Lasso di tempo: at 24 weeks
|
Number of patients with worst-grade toxicities following NCI Common Toxicity Criteria: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death
|
at 24 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie della pelle
- Neoplasie
- Neoplasie per sede
- Malattie del seno
- Neoplasie mammarie
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Ormoni, sostituti ormonali e antagonisti ormonali
- Inibitori della chinasi proteica
- Antagonisti ormonali
- Inibitori dell'aromatasi
- Inibitori della sintesi di steroidi
- Antagonisti degli estrogeni
- Erlotinib cloridrato
- Letrozolo
Altri numeri di identificazione dello studio
- VICC BRE 0303
- VU-VICC-BRE-0303
- VU-VICC-030592
- GENENTECH-VU-VICC-BRE-0303
- NOVARTIS-VU-VICC-BRE-0303
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su erlotinib hydrochloride
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California e altri collaboratoriCompletatoCarcinoma polmonare non a piccole celluleStati Uniti
-
PfizerCompletatoCarcinoma, polmone non a piccole celluleStati Uniti
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatoCancro del polmone non a piccole cellule metastatico | Cancro del polmone non a piccole cellule ricorrenteStati Uniti
-
M.D. Anderson Cancer CenterCompletato
-
New Mexico Cancer Care AllianceCompletatoTumori maligni solidi avanzatiStati Uniti
-
University of ChicagoNational Cancer Institute (NCI)CompletatoMesotelioma peritoneale malignoStati Uniti
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.CompletatoCarcinoma, polmone non a piccole celluleStati Uniti
-
Merck Sharp & Dohme LLCCompletatoCarcinoma, polmone non a piccole cellule
-
PharmaMarCompletatoTumori solidi maligni avanzatiSpagna, Stati Uniti
-
Tragara Pharmaceuticals, Inc.CompletatoCarcinoma polmonare non a piccole cellule ricorrenteStati Uniti